Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Several new antifungals are currently in late-stage development, including those with novel pharmacodynamics/mechanisms of action that represent new antifungal classes (manogepix, olorofim, ATI-2307, GR-2397). Others include new agents within established classes or with mechanisms of action similar to clinically available antifungals (ibrexafungerp, rezafungin, oteseconazole, opelconazole, MAT2203) that have been modified in order to improve certain characteristics, including enhanced pharmacokinetics and greater specificity for fungal targets. Many of the antifungals under development also have activity against Candida and Aspergillus strains that have reduced susceptibility or acquired resistance to azoles and echinocandins, whereas others demonstrate activity against species that are intrinsically resistant to most clinically available antifungals. The tolerability and drug–drug interaction profiles of these new agents also appear to be promising, although the number of human subjects that have been exposed to many of these agents remains relatively small. Overall, these agents have the potential for expanding our antifungal armamentarium and improving clinical outcomes in patients with invasive mycoses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Fungal Cell Wall: Structure, Biosynthesis, and Function
Gow, N. A. R., Latge, J.-P., & Munro, C. A. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0035-2016 · Cited by 1,423 · cited 1×
“This disruption leads to the loss of uridine-5′-monophosphate (UMP) and uridine-5′-triphosphate (UTP), which are important for the production of various cell wall components, as well as cytosine, thymine, and uracil, and also in cell cycle regulation [45].”
BackgroundCandida albicans Cell Wall Proteins
Chaffin, W. L. (2008) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00032-07 · Cited by 515
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
Self-citationPark, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Larkin, E., Hager, C., Chandra, J., Mukherjee, P. K., Retuerto, M., Salem, I., Long, L., Isham, N., Kovanda, L., Borroto-Esoda, K., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02396-16 · Cited by 395
The cell wall architecture of Candida albicans wild‐type cells and cell wall‐defective mutants
Kapteyn, J. C., Hoyer, L. L., Hecht, J. E., Müller, W. H., Andel, A., Verkleij, A. J., Makarow, M., Van Den Ende, H., & Klis, F. M. (2000) · Molecular Microbiology · doi:10.1046/j.1365-2958.2000.01729.x · Cited by 328
Garcia-Effron, G., Katiyar, S. K., Park, S., Edlind, T. D., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00262-08 · Cited by 323
Bowman, J. C., Hicks, P. S., Kurtz, M. B., Rosen, H., Schmatz, D. M., Liberator, P. A., & Douglas, C. M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.3001-3012.2002 · Cited by 303 · cited 4×
“1,3-β-D-glucan is a major cell wall component of many pathogenic fungi; thus, inhibiting its synthesis results in osmotic instability and eventual cell lysis [82,84].”
BackgroundResultInfluentialFunctional and Structural Diversity in the Als Protein Family of Candida albicans
Sheppard, D. C., Yeaman, M. R., Welch, W. H., Phan, Q. T., Fu, Y., Ibrahim, A. S., Filler, S. G., Zhang, M., Waring, A. J., & Edwards, J. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401929200 · Cited by 300
F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Oliver, J. D., Sibley, G. E. M., Beckmann, N., Dobb, K. S., Slater, M. J., McEntee, L., du Pré, S., Livermore, J., Bromley, M. J., Wiederhold, N. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608304113 · Cited by 289
Self-citationShaw, K. J., & Ibrahim, A. S. (2020) · Journal of Fungi · doi:10.3390/jof6040239 · Cited by 229
In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species
Andes, D., Diekema, D. J., Pfaller, M. A., Bohrmuller, J., Marchillo, K., & Lepak, A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01584-09 · Cited by 226
Warrilow, A. G. S., Hull, C. M., Parker, J. E., Garvey, E. P., Hoekstra, W. J., Moore, W. R., Schotzinger, R. J., Kelly, D. E., & Kelly, S. L. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03707-14 · Cited by 173
Watanabe, N.-A., Miyazaki, M., Horii, T., Sagane, K., Tsukahara, K., & Hata, K. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00731-11 · Cited by 169 · cited 1×
“Manogepix appears to have fungal-specific activity, as it does not inhibit the human inositol acyltransferase, Pigw, at clinically relevant concentrations [38].”
BackgroundSafety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults
Sandison, T., Ong, V., Lee, J., & Thye, D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-16 · Cited by 161
Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis
Santangelo, R., Paderu, P., Delmas, G., Chen, Z.-W., Mannino, R., Zarif, L., & Perlin, D. S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2356-2360.2000 · Cited by 150
Hata, K., Horii, T., Miyazaki, M., Watanabe, N.-A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00366-11 · Cited by 149 · cited 1×
“The in vitro activity of manogepix has translated into in vivo efficacy in animal models of aspergillosis, fusariosis, scedoporiosis, coccidioidomycosis, and mucormycosis caused by Rhizopus arrhizus [24,27,31,35,36].”
BackgroundThe antifungal arsenal: alternative drugs and future targets
Wiederhold, N. P. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.09.002 · Cited by 149
Self-citationIn Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
Shaw, K. J., Schell, W. A., Covel, J., Duboc, G., Giamberardino, C., Kapoor, M., Moloney, M., Soltow, Q. A., Tenor, J. L., Toffaletti, D. L., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00523-18 · Cited by 121
In Vitro and In Vivo Antifungal Activities of T-2307, a Novel Arylamidine
Mitsuyama, J., Nomura, N., Hashimoto, K., Yamada, E., Nishikawa, H., Kaeriyama, M., Kimura, A., Todo, Y., & Narita, H. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01159-07 · Cited by 111 · cited 2×
“ATI-2307 (formerly T-2307) is an aromatic diamidine with a structure similar to pentamidine that was identified in a screen of specific compounds in the chemical library at Toyama Chemical Company [65].”
Backgrounddu Pré, S., Beckmann, N., Almeida, M. C., Sibley, G. E. M., Law, D., Brand, A. C., Birch, M., Read, N. D., & Oliver, J. D. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00231-18 · Cited by 111 · cited 3×
“Other effects have also been observed in Aspergillus following exposure to this agent, including inhibition of conidial germination; slowing of germ tube and hyphal growth; hyphal lysis; and, finally, cell death with prolonged exposure (120 h), suggesting that the effects of olorofim change from fungistatic to fungici…”
BackgroundResultInfluentialZhao, Y., Prideaux, B., Nagasaki, Y., Lee, M. H., Chen, P.-Y., Blanc, L., Ho, H., Clancy, C. J., Nguyen, M. H., Dartois, V., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-17 · Cited by 102
Lamoth, F., & Alexander, B. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00234-15 · Cited by 100
Castanheira, M., Duncanson, F. P., Diekema, D. J., Guarro, J., Jones, R. N., & Pfaller, M. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05414-11 · Cited by 98
CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility
Krishnan, B. R., James, K. D., Polowy, K., Bryant, B. J., Vaidya, A., Smith, S., & Laudeman, C. P. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2016.89 · Cited by 98
Pfaller, M. A., Messer, S. A., Motyl, M. R., Jones, R. N., & Castanheira, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01588-12 · Cited by 98
Alkhazraji, S., Gebremariam, T., Alqarihi, A., Gu, Y., Mamouei, Z., Singh, S., Wiederhold, N. P., Shaw, K. J., & Ibrahim, A. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01735-19 · Cited by 97 · cited 2×
“The in vitro activity of manogepix has translated into in vivo efficacy in animal models of aspergillosis, fusariosis, scedoporiosis, coccidioidomycosis, and mucormycosis caused by Rhizopus arrhizus [24,27,31,35,36].”
BackgroundMethodSelf-citationIbrexafungerp: A novel oral glucan synthase inhibitor
Davis, M. R., Donnelley, M. A., & Thompson, G. R. (2020) · Medical Mycology · doi:10.1093/mmy/myz083 · Cited by 91
Wiederhold, N. P., Locke, J. B., Daruwala, P., & Bartizal, K. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky280 · Cited by 91
Self-citationJiménez-Ortigosa, C., Perez, W. B., Angulo, D., Borroto-Esoda, K., & Perlin, D. S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00833-17 · Cited by 89
Spec, A., Pullman, J., Thompson, G. R., Powderly, W. G., Tobin, E. H., Vazquez, J., Wring, S. A., Angulo, D., Helou, S., Pappas, P. G., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz277 · Cited by 88
Pfaller, M. A., Messer, S. A., Rhomberg, P. R., Borroto-Esoda, K., & Castanheira, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00161-17 · Cited by 84
CD101: a novel long-acting echinocandin
Zhao, Y., Perez, W. B., Jiménez‐Ortigosa, C., Hough, G., Locke, J. B., Ong, V., Bartizal, K., & Perlin, D. S. (2016) · Cellular Microbiology · doi:10.1111/cmi.12640 · Cited by 81
Wiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Birch, M., Law, D., Rex, J. H., Catano, G., & Patterson, T. F. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00999-18 · Cited by 80 · cited 2×
“immitis [50,59], and is consistent with the time-dependent activity described in vitro [46].”
BackgroundResultSelf-citationGhannoum, M., Long, L., Larkin, E. L., Isham, N., Sherif, R., Borroto-Esoda, K., Barat, S., & Angulo, D. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00244-18 · Cited by 80 · cited 2×
“terreus, as well as cryptic species and strains that are azoleresistant [83,85,94,95].”
BackgroundResultLepak, A. J., Zhao, M., & Andes, D. R. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01572-18 · Cited by 79
Oteseconazole: An Advance in Treatment of Recurrent Vulvovaginal Candidiasis
Sobel, J. D., & Nyirjesy, P. (2021) · Future Microbiology · doi:10.2217/fmb-2021-0173 · Cited by 78
Yamashita, K., Miyazaki, T., Fukuda, Y., Mitsuyama, J., Saijo, T., Shimamura, S., Yamamoto, K., Imamura, Y., Izumikawa, K., Yanagihara, K., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00374-19 · Cited by 77
Discovery of a Novel Class of Orally Active Antifungal β-1,3- d -Glucan Synthase Inhibitors
Walker, S. S., Xu, Y., Triantafyllou, I., Waldman, M. F., Mendrick, C., Brown, N., Mann, P., Chau, A., Patel, R., Bauman, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00432-11 · Cited by 75
Warrilow, A. G. S., Parker, J. E., Price, C. L., Nes, W. D., Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., Kelly, D. E., & Kelly, S. L. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00349-16 · Cited by 75
Schell, W. A., Jones, A. M., Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., & Alexander, B. D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01817-16 · Cited by 74
Wiederhold, N. P., Najvar, L. K., Shaw, K. J., Jaramillo, R., Patterson, H., Olivo, M., Catano, G., & Patterson, T. F. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01120-19 · Cited by 71
Self-citationZhao, M., Lepak, A. J., VanScoy, B., Bader, J. C., Marchillo, K., Vanhecker, J., Ambrose, P. G., & Andes, D. R. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02542-17 · Cited by 68
Lockhart, S. R., Fothergill, A. W., Iqbal, N., Bolden, C. B., Grossman, N. T., Garvey, E. P., Brand, S. R., Hoekstra, W. J., Schotzinger, R. J., Ottinger, E., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02770-15 · Cited by 67
Self-citationNunnally, N. S., Etienne, K. A., Angulo, D., Lockhart, S. R., & Berkow, E. L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01692-19 · Cited by 66
Schell, W. A., Jones, A. M., Borroto-Esoda, K., & Alexander, B. D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-17 · Cited by 66 · cited 1×
“auris [88]; against which, antibiofilm activity has also been demonstrated [89,90].”
BackgroundRivero-Menendez, O., Cuenca-Estrella, M., & Alastruey-Izquierdo, A. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz078 · Cited by 66
A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis
Brand, S. R., Sobel, J. D., Nyirjesy, P., Ghannoum, M. A., Schotzinger, R. J., & Degenhardt, T. P. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1204 · Cited by 61
Seyedmousavi, S., Chang, Y. C., Law, D., Birch, M., Rex, J. H., & Kwon-Chung, K. J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00129-19 · Cited by 56
Nishimoto, A. T., Wiederhold, N. P., Flowers, S. A., Zhang, Q., Kelly, S. L., Morschhäuser, J., Yates, C. M., Hoekstra, W. J., Schotzinger, R. J., Garvey, E. P., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00341-19 · Cited by 52
Self-citationNishikawa, H., Fukuda, Y., Mitsuyama, J., Tashiro, M., Tanaka, A., Takazono, T., Saijo, T., Yamamoto, K., Nakamura, S., Imamura, Y., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx020 · Cited by 51
The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida auris
Wiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Patterson, H., Connell, A., Fukuda, Y., Mitsuyama, J., Catano, G., & Patterson, T. F. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02198-19 · Cited by 50
Self-citationArendrup, M. C., Chowdhary, A., Jørgensen, K. M., & Meletiadis, J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00656-20 · Cited by 49
Wiederhold, N. P., Najvar, L. K., Fothergill, A. W., Bocanegra, R., Olivo, M., McCarthy, D. I., Fukuda, Y., Mitsuyama, J., & Patterson, T. F. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv398 · Cited by 48
Self-citationWiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Pizzini, J., Catano, G., & Patterson, T. F. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx422 · Cited by 43
Self-citationElewski, B., Brand, S., Degenhardt, T., Curelop, S., Pollak, R., Schotzinger, R., Tavakkol, A., Alonso‐Llamazares, J., Ashton, S. J., Bhatia, N., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19224 · Cited by 42
Pharmacological basis of CD101 efficacy: exposure shape matters
Lakota, E. A., Bader, J. C., Ong, V., Bartizal, K., Miesel, L., Andes, D. R., Bhavnani, S. M., Rubino, C. M., Ambrose, P. G., & Lepak, A. J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00758-17 · Cited by 40
Wiederhold, N. P., Najvar, L. K., Fothergill, A. W., Bocanegra, R., Olivo, M., McCarthy, D. I., Kirkpatrick, W. R., Fukuda, Y., Mitsuyama, J., & Patterson, T. F. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04228-14 · Cited by 36 · cited 1×
“In vivo efficacy has also been reported in animal models of invasive candidiasis, cryptococcosis, and aspergillosis [65,70,71,73,74].”
BackgroundSelf-citationBreak, T. J., Desai, J. V., Natarajan, M., Ferre, E. M. N., Henderson, C., Zelazny, A. M., Siebenlist, U., Hoekstra, W. J., Schotzinger, R. J., Garvey, E. P., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx352 · Cited by 34
Jørgensen, K. M., Astvad, K. M. T., & Arendrup, M. C. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00730-20 · Cited by 33
Pappas, P., Kullberg, B. J., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., McCarty, T. P., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa439.457 · Cited by 17
Cited by
Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods
Satora, M., Grunwald, A., Zaremba, B., Frankowska, K., Żak, K., Tarkowski, R., & Kułak, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165376 · Cited by 84
“Oteseconazole—mechanism of action [53].”
BackgroundInfluentialFungal biofilms in human health and disease
Ramage, G., Kean, R., Rautemaa-Richardson, R., Williams, C., & Lopez-Ribot, J. L. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01147-0 · Cited by 72
Antifungal therapy of Candida biofilms: Past, present and future
Ajetunmobi, O. H., Badali, H., Romo, J. A., Ramage, G., & Lopez-Ribot, J. L. (2023) · Biofilm · doi:10.1016/j.bioflm.2023.100126 · Cited by 52
“However, the emergence of resistance, through mutations in the gene encoding the target enzyme, may limit their efficacy [36].”
BackgroundNew Antifungals for Vulvovaginal Candidiasis: What Is Their Role?
Sobel, J. D. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad002 · Cited by 23
Metadata
- Authors
- Wiederhold, N. P.
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2022-08-16
- Volume
- 8
- Issue
- 8
- Pages
- 857
- ISSN
- 2309-608X (ISSN-L)
- OpenAlex
- W4292295113
- Cited by
- 67
- References
- 61
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.